Molecule Details
| InChIKey | GSNHKUDZZFZSJB-QYOOZWMWSA-N |
|---|---|
| Canonical SMILES | Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 8.6 |
| Source | BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB04835 |
|---|---|
| Drug Name | Maraviroc |
| CAS Number | 376348-65-1 |
| Groups | approved investigational |
| ATC Codes | J05AX09 |
| Description | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but w... |
Categories: Anti-HIV Agents Anti-Infective Agents Anti-Retroviral Agents Antiinfectives for Systemic Use Antiviral Agents Antivirals for Systemic Use CCR5 Co-receptor Antagonist CCR5 Receptor Antagonists Cyclohexanes Cycloparaffins Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates Direct Acting Antivirals HIV Fusion Inhibitors Hepatotoxic Agents Triazoles Viral Fusion Protein Inhibitors
Cross-references: BindingDB: 50334986 ChEBI: 63608 CHEMBL1201187 ChemSpider: 20078004 Drugs Product Database (DPD): 20160 Guide to Pharmacology: 806 IUPHAR: 806 PDB: MRV PharmGKB: PA164768835 PubChem:3002977 PubChem:46508040 RxCUI: 620216 Therapeutic Targets Database: DNC001487 Wikipedia: Maraviroc ZINC: ZINC000100003902